Pertuzumab (trade name: Perjeta®) is another HER2 monoclonal antibody that blocks formation of the HER2 dimer and its receptor by binding HER2, inhibiting activation of the PI3K-PKB/Akt signaling pathway, inhibiting the activity of cancer cells, slowing tumor growth, and reducing recurrence rate (Osako et al., 2015; Williams et al., 2017; Paek et al., 2019). The gene discussed is ERBB2; the disease is cancer.